HIV-1-Specific Mucosal CD8+ Lymphocyte Responses in the Cervix of HIV-1-Resistant Prostitutes in Nairobi

Rupert Kaul, Francis A. Plummer, Joshua Kimani, Tao Dong, Peter Kiama, Timothy Rostron, Ephantus Njagi, Kelly S. MacDonald, Job J. Bwayo, Andrew J. McMichael and Sarah L. Rowland-Jones

J Immunol 2000; 164:1602-1611; doi: 10.4049/jimmunol.164.3.1602
http://www.jimmunol.org/content/164/3/1602

References
This article cites 37 articles, 6 of which you can access for free at:
http://www.jimmunol.org/content/164/3/1602.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
HIV-1-Specific Mucosal CD8⁺ Lymphocyte Responses in the Cervix of HIV-1-Resistant Prostitutes in Nairobi

Rupert Kaul,* Rupert Kaul,* Francis A. Plummer,*§ Joshua Kimani,* Tao Dong,† Peter Kiama,‡ Timothy Rostron,† Ephratus Njagi,* Kelly S. MacDonald,*§ Job J. Bwayo,* Andrew J. McMichael,* and Sarah L. Rowland-Jones‡

Understanding how individuals with a high degree of HIV exposure avoid persistent infection is paramount to HIV vaccine design. Evidence suggests that mucosal immunity, particularly virus-specific CTL, could be critically important in protection against sexually acquired HIV infection. Therefore, we have looked for the presence of HIV-specific CD8⁺ T cells in cervical mononuclear cells from a subgroup of highly HIV-exposed but persistently seronegative female sex workers in Nairobi. An enzyme-linked immunospot assay was used to measure IFN-γ release in response to known class I HLA-restricted CTL epitope peptides using effector cells from the blood and cervix of HIV-1-resistant and -infected sex workers and from lower-risk uninfected controls. Eleven of 16 resistant sex workers had HIV-specific CD8⁺ T cells in the cervix, and a similar number had detectable responses in blood. Where both blood and cervical responses were detected in the same individual, the specificity of the responses was similar. Neither cervical nor blood responses were detected in lower-risk control donors. HIV-specific CD8⁺ T cell frequencies in the cervix of HIV-resistant sex workers were slightly higher than in blood, while in HIV-infected donor cervical response frequencies were markedly lower than blood, so that there was relative enrichment of cervical responses in HIV-resistant compared with HIV-infected donors. HIV-specific CD8⁺ T cell responses in the absence of detectable HIV infection in the genital mucosa of HIV-1-resistant sex workers may be playing an important part in protective immunity against heterosexual HIV-1 transmission. The Journal of Immunology, 2000, 164: 1602–1611.

Recent interest has focused on local HIV-specific immune responses in the genital tract of individuals who remain uninfected despite repeated sexual exposure to HIV-1 (highly exposed persistently seronegative, HEPS). Mucosal HIV-1-specific IgA is found in many HEPS subjects (6–8), but it is thought that HIV-specific humoral responses alone may be insufficient to protect against infection (1). HIV-1-specific Th and CTL immune responses have been detected in the blood of HEPS individuals (8–15). In addition, a stepwise increase in the frequency of bulk CTL recognizing HIV-1 env has been seen with increasing levels of prior HIV exposure in HEPS prostitutes, suggesting that HIV-specific CTL may be causally associated with protection against HIV-1 infection (16). However, although CD8⁺ lymphocytes from HEPS donors can protect against systemic HIV-1 challenge in a SCID/beige mouse model (17), other murine experiments have shown that mucosal rather than systemic (splenic) HIV-specific CTL are necessary to confer resistance to mucosal viral transmission (18). Recent work has shown that transient infection of the colonic mucosa in rhesus macaques can induce class I HLA-restricted CTL recognizing SIV env and that the presence of mucosal CTL correlates absolutely with protection against subsequent colonic viral challenge (19).

These studies suggest that while HIV-specific CTL are likely to be important in mediating protective immunity, these responses may need to be present in the genital tract to prevent heterosexual HIV-1 acquisition. Although HIV-1-specific CTL have been demonstrated in the genital tract of HIV-1-infected women (20), there
are no previous data regarding mucosal CTL responses in the genital tract of exposed, uninfected populations. This may be partly due to the difficulties inherent in demonstrating low-frequency CTL using samples obtained from a site with a rich microbial flora and that contain relatively few T lymphocytes. The IFN-γ enzyme-linked immunospot (ELISPOT) assay, which has been previously used to document HIV-specific CD8⁺ responses in the blood of both HIV-1-infected and HEPS donors (15, 21), provides an estimate of Ag-specific CD8⁺ lymphocyte frequencies that correlates closely with those measured by either tetrameric MHC-peptide complexes or limiting dilution CTL assays (22). ELISPOT offers the added advantages of being an overnight assay, thereby minimizing the effect of bacterial contamination, and of requiring fewer input cells than standard bulk CTL assays (15, 22, 23). For these reasons, we have used the IFN-γ ELISPOT to estimate CTL frequencies in the cervix and blood of HEPS sex workers.

In an observational cohort study of the epidemiology and immunology of HIV-1 in sex workers in a slum area of Nairobi (24, 25), we have identified a subgroup of women who exhibit relative resistance to HIV-1 infection (26). It is estimated that these women have over 60 unprotected sexual exposures to HIV-1 per year, despite behavioral counseling and provision of condoms; their exposure is uniformly through vaginal intercourse. Resistance in this subgroup is associated with systemic HIV-1-specific Th and CTLs (7, 15), mucosal HIV-1-specific IgA responses (7), and certain MHC class I/II alleles (27), but not with polymorphisms in CCR5 or altered cellular susceptibility to HIV-1 (3). We now report the occurrence and specificity of HIV-1-specific, IFN-γ-secreting, CD8⁺ T lymphocytes in both cervix and blood of these HIV-1-resistant sex workers.

Materials and Methods

Study populations

Women were enrolled through a dedicated sex worker clinic in the Pumwani district of Nairobi, Kenya, and were classified as HIV-1 resistant if they were seronegative on enrollment and remained both seronegative and PCR negative for at least 3 years of continuing sex work (26). We studied systemic and cervical responses to previously defined HIV-1 CTL epitopes in a subgroup of HIV-1-resistant and HIV-1-infected sex workers attending the annual clinic resurvey between October 1998 and February 1999. The influencer of these women was sexually transmitted infections (STI) on immune responses in the genital tract mucosa is unknown, and for this reason any women with clinical or laboratory evidence of STI were excluded. Lower-risk HIV-1-uninfected control women were enrolled from a mother-child health care clinic in the Pumwani district of Nairobi and from an infertility clinic in Nairobi’s Kenyatta National Hospital. A physical examination was performed, and blood was drawn for HIV-1 and syphilis (rapid plasma reagin) serology. In both groups, women with clinical or laboratory evidence of cervicitis were excluded, as were those with any history of commercial sex work.

Informed consent was obtained from all study participants, and the study conformed to ethical guidelines from the University of Manitoba and the University of Nairobi.

General laboratory methods

Molecular HLA typing was performed on all study subjects using amplification refractory mutation system-PCR with sequence-specific primers, as previously described (28). HIV-1 serological testing employed a synthetic peptide enzyme immunoassay (Detect HIV, Biochem ImmunoSystems, Montreal, Canada), and positive tests were confirmed using a recombinant Ag enzyme immunoassay (Recombigen HIV-1/2 EIA, Cambridge Biotech Corporation, Galway, Ireland). All HIV-1-seronegative sex workers were confirmed to be HIV-1-uninfected employing a PCR system that uses primers for env, nef, and vif HIV-1 provirus genes (26, 29), which have been specifically adapted to detect African clades.

Flow cytometry analysis

Peripheral blood T lymphocyte subset analysis was performed using anti-CD4 FITC/CD8 PE (Becton Dickinson Immunocytometry Systems, Mountain View, CA). Cervical mononuclear cell subpopulations were characterized from cryopreserved specimens using anti-CD3 FITC, anti-CD4 Tri-color, and anti-CD8 PE. After incubation with mAbs for 30 min at 4°C, 10⁶ cells were washed in PBS with 1% FBS, fixed, and analyzed using a FACScanto flow cytometer (Becton Dickinson Immunocytometry Systems) with CellQuest software. Gating was used to select the lymphocyte fraction.

HIV-1 CTL epitope selection and peptide synthesis

HIV-1 peptides were selected from a panel of previously defined A, B, and D clade CTL epitopes. Epitope selection was based on 1) the class I HLA haplotype of the donor; and 2) where possible, on the results of previous systemic HIV-1-specific CTL assays in this study population (15). Peptides were synthesized by F-moc chemistry using a Zinnser Analytical synthesizer (Advanced Chemtech, Louisville, KY), and purity was established by HPLC.

Sampling and transport

Blood was drawn into 12-ml tubes containing the anticoagulant acid citrate dextrose. Cervical samples were obtained using a cytobrush (Histobrush; Spectrum Labs, Dallas, TX), which was inserted into the cervical os, gently rotated through 360°, and transferred immediately into 5 ml of RPMI 1640. To avoid contamination with blood, the cytobrush specimen was obtained before other sampling (STI cultures, etc.), was not collected from women who were actively menstruating, and was rejected if it contained visible blood. All samples were transported to the laboratory within 2 h. The cytobrush was vigorously agitated and discarded, and the remaining cell suspension was agitated to loosen any mucus clumps. Both cervical mononuclear cells (CMC) and PBMC were then isolated by Ficoll-Hypaque gradient centrifugation, washed, and resuspended in RPMI 1640 with 10% FCS (R/10).

IFN-γ ELISPOT assays

A modified ELISPOT assay was used to detect peptide-specific IFN-γ release by either freshly separated or cryopreserved PBMC, and by freshly separated CMC, as previously described (15). First, 96-well nitrocellulose plates were precoated with a first layer IFN-γ mAb, 1-DIK (MABTECH, Nacka, Sweden). PBMC or CMC were then added in duplicate wells, either with predefined HIV-1 class I-restricted peptide epitopes at a concentration of 20 μM or with no peptide (negative control) or in 1:100 PHA (Murex Biotech, Dartford, U.K.; positive control). PBMC assays were run at 2 × 10⁵ and 5 × 10⁶/well, while CMC assays were frequently run at a single input concentration due to low cell numbers. Plates were incubated overnight at 37°C in 5% CO₂, then the cells were discarded, and the plate incubated at room temperature for 3 h with a second biotinylated anti-IFN-γ mAb (7-B6-1 biotin; MABTECH), followed by streptavidin-conjugated alkaline phosphatase (MABTECH) for 2 h. Individual IFN-γ-producing cells were detected as dark blue spots using an alkaline phosphatase-conjugate substrate kit (Bio-Rad, Hercules, CA). The spots were counted by eye at an unblinded study investigator, and the numbers were confirmed using a dissecting microscope (magnification, ×40).

HIV-1-specific IFN-γ responses were reported as number of spot-forming units (SFU)/10⁵ mononuclear cells, after subtracting background rates of spontaneous IFN-γ secretion. The background rate of IFN-γ secretion was defined as the number of SFU/10⁵ mononuclear cells incubated in media alone, without peptide stimulation. Values reported generally represent the HIV-1 responses quantified at the highest cell input numbers. An HIV-1-specific ELISPOT response was defined as follows: 1) IFN-γ release seen in response to 1:100 PHA (criterion for an adequate assay); 2) ≥20 HIV-1-specific SFU/10⁵ mononuclear cells; 3) IFN-γ release in HIV-1 peptide wells exceeded background (spontaneous) rates of IFN-γ release by a factor of at least 2; and 4) if serial dilutions had been established, a titratable response was required.

CD8⁺ lymphocyte depletion assays

CD8⁺ lymphocyte depletion was performed using anti-CD8⁺ Ab-coated immunomagnetic beads (Dynabeads HLA cell prep I; Dynal, Lake Success, NY), according to manufacturer’s instructions. Significant reduction of an ELISPOT response was defined as a ≥50% reduction in HIV-1-specific IFN-γ release after CD8⁺ lymphocyte depletion.

Data analysis

Statistical analysis used the SPSS for Windows Rel. 9.0.0 1998 package (SPSS, Chicago, IL). Comparison of means between study groups was performed by one-way ANOVA.
Results

Description of study subjects

In total, 26 HIV-1-resistant sex workers and 16 HIV-1-infected sex workers were enrolled between October 1998 and February 1999. The cervical samples from 10 HIV-1-resistant and 5 HIV-1-infected sex workers were inadequate for analysis (no response to PHA), so simultaneous cervical and systemic responses could be studied for 16 resistant and 11 HIV-1-infected sex workers. The mean cytobrush yield for adequate cervical assays was $4.3 \times 10^5$ CMC (range, $8 \times 10^4$ – $1.2 \times 10^6$ CMC), and for inadequate assays was $6 \times 10^4$ CMC. The cell yields of adequate cervical samples did not differ between positive and negative assays ($3.7 \times 10^5$ and $6.5 \times 10^5$ cells, respectively; $p = 0.1$). HIV-1 infection status did not influence cell yield from cervical cytobrushes ($4.6 \times 10^5$ CMC for HIV-1-infected and $4.1 \times 10^5$ for HIV-1-resistant sex workers; $p = 0.7$). HIV-1-infected subjects had a mean blood CD$4^+$ lymphocyte count of 416/mm$^3$ (160–780/mm$^3$) and CD$8^+$ count of 1164/mm$^3$ (770–2730/mm$^3$). HIV-1-resistant sex workers had a mean CD$4^+$ count of 975/mm$^3$ (660–1602/mm$^3$) and CD$8^+$ count of 894/mm$^3$ (320–1360/mm$^3$).

Phenotypic analysis of CMC

Phenotypic analysis was performed on CMC specimens from three HIV-1-resistant sex workers (representative example shown in Fig. 1), and two HIV-1-infected sex workers. A well-defined CD$8^+$ lymphocyte population was present in all samples, with CD$8^+$ lymphocytes comprising 11.8–24.1% of the gated lymphocyte subpopulation (0.1–0.4% of total events). No differences were noted in CD$8^+$ lymphocyte frequencies according to HIV-1 infection status.

HIV-1-specific ELISPOT responses are common in the blood and cervix of HIV-1-resistant and -infected sex workers

HIV-1-specific IFN-$\gamma$ responses were found in the cervix and blood of 11 of 16 (69%) HIV-1-resistant sex workers (Table I; Fig. 2) and in the cervix and blood of 8 of 11 (73%) HIV-1-infected sex workers (Table I). HIV-1-specific responses in the cervix were associated with a systemic response to the same HIV-1 CTL epitope in 9 of 11 (82%) resistant and 7 of 8 (88%) infected sex workers. HIV-1-specific responses were localized to the blood in...
Table I. Frequency and HIV-1 epitope specificity of IFN-γ ELISPOT responses in the blood and cervix of 16 HIV-1-resistant Kenyan sex workers, 11 HIV-1-infected Kenyan sex workers, and 7 HIV-1-uninfected, lower-risk Kenyan controls

<table>
<thead>
<tr>
<th>Subject</th>
<th>HLA Type</th>
<th>HIV-1 CTL Epitope</th>
<th>HLA Restricted</th>
<th>Protein (clade)</th>
<th>Systemic Frequency</th>
<th>Cervical Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-1-resistant sex workers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML851</td>
<td>A*0101,6802, B58,*8101</td>
<td>TPGGVR, YPLR</td>
<td>B7(*8101)</td>
<td>nef(B)</td>
<td>22</td>
<td>80</td>
</tr>
<tr>
<td>ML889</td>
<td>A1,*6802</td>
<td>VR, PTV</td>
<td>A*6802</td>
<td>pol(A)</td>
<td>80</td>
<td>20</td>
</tr>
<tr>
<td>ML1200</td>
<td>A*0201,3301, B58,15</td>
<td>AFOSSMTK</td>
<td>A33</td>
<td>pol(B)</td>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>ML1260</td>
<td>A<em>0201, B</em>1801,1503</td>
<td>YPFLTFGWC</td>
<td>B18</td>
<td>nef(D)</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>ML1275</td>
<td>A1,*3001</td>
<td>LSPRTLNAW</td>
<td>B57/58</td>
<td>p24(A)</td>
<td>24</td>
<td>0</td>
</tr>
<tr>
<td>ML1356</td>
<td>A29,<em>3001, B</em>1503,42</td>
<td>VSFEPIPHY</td>
<td>A29</td>
<td>gp120(B)</td>
<td>24</td>
<td>0</td>
</tr>
<tr>
<td>ML1358</td>
<td>A*0201,6802, B42,57</td>
<td>LSPRTLNAW</td>
<td>B57/58</td>
<td>p24(A)</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>ML1437</td>
<td>A*0201,6802, B53,72</td>
<td>DTVLEDINL</td>
<td>A*6802</td>
<td>pol(A)</td>
<td>85</td>
<td>20</td>
</tr>
<tr>
<td>ML1488</td>
<td>A3,*3002, B49,67</td>
<td>KIRLPRGGK</td>
<td>A3</td>
<td>p17(B)</td>
<td>40</td>
<td>80</td>
</tr>
<tr>
<td>ML1490</td>
<td>A25,36</td>
<td>DLNMMLNIV</td>
<td>B14</td>
<td>p24(A)</td>
<td>95</td>
<td>60</td>
</tr>
<tr>
<td>ML1589</td>
<td>A1,*3002, B58</td>
<td>LSPRTLNAW</td>
<td>B57/58</td>
<td>p24(A)</td>
<td>50</td>
<td>25</td>
</tr>
<tr>
<td>ML1601</td>
<td>A*0202,6802, B47,58</td>
<td>ALKHRAYEL</td>
<td>A2</td>
<td>nef(A/D)</td>
<td>40</td>
<td>10</td>
</tr>
<tr>
<td>ML1611</td>
<td>A1,3</td>
<td>DTVLEDINL</td>
<td>A*6802</td>
<td>pol(A)</td>
<td>128</td>
<td>50</td>
</tr>
<tr>
<td>ML1612</td>
<td>A<em>3002, B</em>44031,57, B*44031,58</td>
<td>LSPRTLNAW</td>
<td>B57/58</td>
<td>p24(A)</td>
<td>120</td>
<td>200</td>
</tr>
<tr>
<td>ML1792</td>
<td>A3,<em>3303, B</em>1402,1516</td>
<td>DLNMMLNIV</td>
<td>B14</td>
<td>p24(A)</td>
<td>20</td>
<td>25</td>
</tr>
<tr>
<td>ML1803</td>
<td>A2, B18,53</td>
<td>ALKHRAYEL</td>
<td>A2</td>
<td>nef(A/D)</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>HIV-1-infected sex workers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML646</td>
<td>A30,74</td>
<td>LSPRTLNAW</td>
<td>B57/58</td>
<td>p24(A)</td>
<td>355</td>
<td>270</td>
</tr>
</tbody>
</table>

HIV-1-uninfected controls

<table>
<thead>
<tr>
<th>Subject</th>
<th>HLA Type</th>
<th>HIV-1 CTL Epitope</th>
<th>HLA Restricted</th>
<th>Protein (clade)</th>
<th>Systemic Frequency</th>
<th>Cervical Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>ML768</td>
<td>A*0201,32</td>
<td>SLNFNTVATL</td>
<td>A2</td>
<td>p17(A)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>ML857</td>
<td>A*3004,6801, B35,*4501</td>
<td>ILKDPVHG</td>
<td>A2</td>
<td>pol(A)</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>ML1211</td>
<td>A*0214,24</td>
<td>SLNFNTVATL</td>
<td>A2</td>
<td>p17(A)</td>
<td>820</td>
<td>15</td>
</tr>
<tr>
<td>ML1387</td>
<td>A*30,3301, B14,18</td>
<td>SLNFNTVATL</td>
<td>A2</td>
<td>p17(B)</td>
<td>892</td>
<td>25</td>
</tr>
<tr>
<td>ML1410</td>
<td>A*2301,3001, B18,42</td>
<td>YPFLTFGWC</td>
<td>B18</td>
<td>p24(B)</td>
<td>1993</td>
<td>930</td>
</tr>
<tr>
<td>ML1535</td>
<td>A<em>3001, B</em>1801,42</td>
<td>YPFLTFGWC</td>
<td>B18</td>
<td>p24(D)</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>ML1549</td>
<td>A*0202,24, B47,4902</td>
<td>SLNFNTVATL</td>
<td>A2</td>
<td>p17(B)</td>
<td>140</td>
<td>200</td>
</tr>
<tr>
<td>ML1575</td>
<td>A*0201, B42,70</td>
<td>SLNFNTVATL</td>
<td>A2</td>
<td>p17(A)</td>
<td>20</td>
<td>300</td>
</tr>
<tr>
<td>ML1592</td>
<td>A*0201, B15</td>
<td>SLNFNTVATL</td>
<td>A2</td>
<td>p17(B)</td>
<td>494</td>
<td>0</td>
</tr>
<tr>
<td>ML1665</td>
<td>A1,2</td>
<td>SLNFNTVATL</td>
<td>A2</td>
<td>p17(B)</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>MCH</td>
<td>A29,53</td>
<td>VSFEPIPHY</td>
<td>A29</td>
<td>gp120(B)</td>
<td>13</td>
<td>15</td>
</tr>
</tbody>
</table>

1. HIV-1 resistance as defined by Fowke et al. (26).
2. Responses meeting the definition of a positive HIV-1-specific IFN-γ ELISPOT (see Materials and Methods) are shown in bold. In general, HIV-1-specific responses were considered positive if they exceeded background (spontaneous) rates of IFN-γ release by a factor of ≥2 and were present at a frequency of ≥20 SFU/10^6 input cells.
3. HIV-1-specific SFU/10^6 PBMC.
4. HIV-1-specific SFU/10^6 CMC.
three subjects (2 of 11 HIV-resistant and 1 of 8 HIV-infected subjects) and to the cervix in three subjects (2 of 11 resistant and 1 of 8 infected subjects). The ELISPOT responses of HIV-1-infected sex workers tended to be greater in magnitude than those in resistant women, both in blood (606.4 vs 62.2 SFU/10⁶ PBMC; \( p < 0.01 \)) and cervix (189.4 vs 78.4 SFU/10⁶ CMC; \( p < 0.2 \)). Rates of background (spontaneous) IFN-γ release did not vary between subjects with or without positive HIV-1-specific responses, either in the blood (27.8 vs 22.1 SFU/10⁶ PBMC, respectively; \( p < 0.4 \)) or in the cervix (73.2 vs 67.2 SFU/10⁶ CMC, respectively; \( p < 0.8 \)).

A number of HIV-1 CTL epitopes were recognized by resistant women in both the blood and cervix, most commonly DTVLEDINL (A*6802, clade A pol; three subjects) and LSPRTLNAW (B57/58 clade A p24; two subjects). The most common CTL epitopes recognized by HIV-1-infected subjects were SLYNTVATL (A2, clade B p17; three subjects); LSPRTLNAW (B57/58, clade A p24; one subject); and YPLTFGWCF (B18, clade D nef; two subjects). However, the selection of peptide epitopes for use in the ELISPOT assays differed between HIV-1-resistant and -infected study subjects and was determined by subject HLA type and previous blood ELISPOT responses (measured as part of an ongoing study of HIV-1-specific systemic immune responses in the cohort).

Follow-up cervical specimens were obtained after a positive ELISPOT assay for one HIV-1-infected and four HIV-1-resistant sex workers. Persistent HIV-1-specific responses were found in the cervix of one of one HIV-1-infected and three of four HIV-1-resistant sex workers after an interval of 5–21 wk. The intensity of cervical responses had increased from baseline in two resistant sex workers (ML889, 20–150 SFU/10⁶ CMC; ML1792, 25–67 SFU/10⁶ CMC), had decreased in one (ML1622, 200–50 SFU/10⁶ CMC), and were no longer detectable in one (ML1589). Data were not available concerning changes in sexual behavior over the intervening period.

**HIV-1-specific IFN-γ responses are enhanced in the cervix of HIV-1-resistant sex workers**

To look at the relative intensity of systemic and cervical responses, a cervical-systemic differential was calculated for each peptide epitope by subtracting the peptide-specific systemic (PBMC) response from the cervical (CMC) response. This showed that the cervical responses were relatively enriched in the HIV-1-resistant group, compared with systemic (mean differential, +13.5 SFU/10⁶; \( p = \text{NS} \)), while in the HIV-1-infected group systemic responses were considerably more intense than cervical (mean differential, −320.2 SFU/10⁶; \( p = 0.008 \) between groups).
HIV-1-specific systemic and genital tract IFN-γ responses are diminished or abrogated by CD8⁺ lymphocyte depletion

CD8⁺ depletion assays were performed using PBMC from 10 HIV-1-resistant and 5 HIV-1-infected sex workers and using cervical specimens from 3 resistant and 3 infected sex workers. In general, PBMC depletion assays were run using cryopreserved samples obtained at the same point in time as the original sample. Due to limited cell numbers in cryopreserved mucosal specimens, cervical CD8⁺ depletions were run using follow-up samples obtained at a later point in time. Bead depletion resulted in a mean depletion of CD8⁺ lymphocytes of 77% (62.2–92.1%) in PBMC assays and of 82% in cervical assays (74.9–89.5%). Systemic responses were diminished or abrogated after CD8⁺ lymphocyte depletion in 8 of 10 (80%) resistant (Fig. 3A) and 5 of 5 (100%) HIV-1-infected (Fig. 3B) sex workers; cervical responses were diminished or abrogated in all HIV-1-resistant and HIV-1-infected individuals (Fig. 4).

HIV-1 CTL epitopes are not recognized in the blood or cervix of lower-risk control women

Responses to class I-restricted HIV-1 CTL epitopes were studied in the blood and cervix of seven HIV-1-uninfected, lower-risk Kenyan women (Table I), largely using peptides to which responses had been detected in at least one HIV-1-resistant sex worker. No HIV-1-specific cellular responses were found in the blood or cervix of these lower-risk controls (Table I; p = 0.02 for both comparisons).
HIV-1-resistant women do not respond to HLA-mismatched HIV-1 peptides

To confirm that these responses were HLA restricted, PBMC or CMC from HIV-1-resistant sex workers (HIV-1 resistance as defined by Fowke et al. (26)) were incubated with HLA class I-mismatched CTL epitopes. The majority of HIV-1 peptides selected had been recognized by at least one HIV-1-resistant woman in HLA-matched assays, including: DTVLEDINL (A*6802, clade A pol); VS-FEPIPIHY (A29, clade B gp120); LSPRTLNAW (B57/58, clade A).

**Table II. HIV-1-specific immune responses demonstrated to date in the 16 HIV-1-resistant study subjects**

<table>
<thead>
<tr>
<th>Study Subject</th>
<th>Cervical ELISPOT</th>
<th>PBMC ELISPOT</th>
<th>HIV-1 env Th Response</th>
<th>HIV-1 env Bulk CTL</th>
<th>HIV-1 Peptide Bulk CTL</th>
<th>HIV-1-Specific Mucosal IgA</th>
<th>HIV-1-Neutralizing Mucosal IgA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ML851</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML889</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1250</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1260</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1275</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1356</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1358</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1437</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1488</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1490</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1589</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1601</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1622</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1643</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1792</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML1803</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* HIV-1 resistance as defined by Fowke et al. (26).
* "1" indicates a positive assay result, and "0" indicates a negative result. Where a space is left blank, the assay has not been previously performed.
* See text for definition of a positive cervical and PBMC ELISPOT.
* Defined as an IL-2 stimulation index of ≥ 4 in response to stimulation by two or more antigenic HIV-1 envelope peptides (7).
* Defined as >10% specific lysis by bulk CTL line of autologous BCL, infected by HIV-1 env/vaccinia construct (16).
* Defined as >10% specific lysis by bulk CTL line of autologous BCL, pulsed with class I HLA-restricted HIV-1 CTL epitope (15).
* Defined as levels of HIV-1-specific cervical or vaginal IgA >2 SD above mean levels found in low-risk Kenyan controls (7).
* Defined as ≥5% (67%) reduction of clade B HIV-1 p24 in culture supernatant, in the presence of purified mucosal IgA (34).
gag); ATPQDLNMML (B53, clade A p24); DLNMMMLIV (B14, clade A p24); and VPLRPMTY (B35, clade B nef). No responses were seen to these HLA-mismatched epitopes in six of six PBMC and two of two CMC specimens from HIV-1-resistant sex workers (data not shown).

**Associations with HIV-1-specific ELISPOT responses**

No association was found between cervical or systemic responses and total CD4⁺ or CD8⁺ lymphocyte counts in either HIV-1-resistant or HIV-1-infected subjects (data not shown). Neither systemic nor mucosal HIV-1-specific IFN-γ responses were associated with sexual risk behaviors as reported by study subjects at the time of study enrollment, including number of clients per day, duration of sex work, or frequency of condom use (data not shown). Because women with STI were excluded from the study, no data was available to examine the possible influence of concurrent STI on systemic or mucosal HIV-1-specific responses.

**Discussion**

This is the first demonstration of HIV-1-specific CD8⁺ lymphocyte responses in the cervix of HIV-exposed, seronegative individuals. The possibility that genital tract CTL might play a key role in protection against sexually acquired HIV-1 infection was suggested by Belyakov et al., who showed that mucosal HIV-specific CD8⁺ CTL conferred long-lasting immune resistance to mucosal viral transmission in mice (18), while systemic (splenic) CTL alone were unable to protect against mucosal transmission. More recently, Murphy-Corb et al. have shown that MHC class I-restricted CTL directed against viral env in the jejunal lamina propria are absolutely correlated with protection from colonic SIV challenge (19).

The exact mechanism by which these mucosal CTL could function is not yet clear. HIV-1 can cross into the submucosa by transcytosis across a tight epithelial barrier, a process that can be inhibited by HIV-specific IgA (30). Furthermore, CD4⁺ and CCR5⁺ cell populations, which are susceptible to productive HIV-1 infection, are present in this region (31, 32). The cervical submucosa is well-supplied with CD8⁺ T lymphocytes, both of a memory (CD45RO⁺) and effector (perforin⁺) phenotype (33), and CD3⁺ cytolytic activity is present in the genital tract throughout the menstrual cycle (31–33). Therefore, we hypothesize that HIV-1-specific cervical CTL in the submucosa may target susceptible host cells, which have undergone productive infection by HIV-1 after viral transcytosis across the epithelial tight membrane.

HIV-specific systemic (blood) responses have been previously described in our study cohort of HIV-1-resistant sex workers (15, 16); however, the vast majority of HIV-1 transmission in this population occurs across the genital mucosa during heterosexual intercourse (25). Therefore, HIV-specific CTL in the cervix might play a more direct role than do systemic responses in immunemediated protection against sexually acquired HIV-1 infection. If these mucosal HIV-specific CTL in the genital tract play a critical role in protection against HIV-1 infection in this prostitute population, then enrichment of HIV-1-specific CD8⁺ responses in the cervix might be predicted, because this is the site of viral exposure. In keeping with this hypothesis, we found that cervical responses were slightly enhanced relative to systemic in HIV-resistant prostitutes, while HIV-infected women showed considerable enrichment of HIV-specific responses in the blood. Although overall responses were weaker in HIV-resistant than HIV-infected prostitutes, their relative enhancement at the site of repeated viral exposure is consistent with the hypothesis that they play a major role in protection against heterosexual transmission of HIV-1.

Musey and colleagues have demonstrated that HIV-1-specific CTL (involving both CD4⁺ and CD8⁺ cells) could be generated from cervical specimens in HIV-1-infected women (20). In these HIV-1-infected women, comparisons of intraindividual cervical and blood CTL specificities also indicated that epitopes recognized by CTL in the cervix were commonly recognized in the blood, although relative frequencies of CTL in cervix and blood were not examined. The importance of these responses in the genital tract of HIV-1-infected individuals is not clear, although they could potentially play a part in reducing HIV transmission to sexual partners.

This study used an IFN-γ ELISPOT assay to demonstrate CD8⁺ lymphocyte-mediated HIV-1-specific responses from cervical and blood specimens. ELISPOT has been previously used to document HIV-specific responses in both HIV-1-infected and HEPS donors (15, 21). Estimates of Ag-specific CD8⁺ lymphocyte frequencies using ELISPOT correlate well with those measured by either tetrameric MHC-peptide complexes or limiting dilution CTL assays (22). However, the ELISPOT technique has the advantage over tetramer staining of increased sensitivity at low precursor frequencies (1/50,000 as opposed to 1/5,000 (23)), and ELISPOT also allows rapid screening of responses against a wide variety of HIV-1 CTL epitopes, many of which are not currently available as MHC-peptide tetramers. In comparison to limiting dilution assays, the ELISPOT is a relatively rapid assay and so is less subject to overgrowth by genital tract flora. In addition, ELISPOT requires fewer effector cells than limiting dilution assays, making it better suited to analysis of samples with relatively few T lymphocytes.

Previous studies of HIV-specific immune responses in the genital tract of HEPS subjects have been confined to the detection of HIV-1-specific IgA, both in this cohort of HIV-1-resistant Kenyan sex workers (7) and other exposed uninfected groups (6, 8). Eight of the 16 (50%) HIV-1-resistant subjects in the present study have been enrolled in previous studies of genital tract IgA (7, 34); either HIV-1-specific IgA or HIV-neutralizing mucosal IgA was found in eight of eight (Table II), including three subjects who had no demonstrable CD8⁺ lymphocyte responses in our study. Several study subjects have also been tested for systemic HIV-1 env-specific Th responses (detected in five of seven) (7); for systemic CTL responses against an HIV-1 env/vaccinia construct (detected in five of nine) (16); and for systemic CTL responses against class I HLA-restricted HIV-1 peptide epitopes (detected in three of three) (15) (Table II). However, many of these data were only available for a small subset of study subjects, and the data were not collected at the same time as those in the current study. Because HIV-specific immune response frequencies may increase or wane over time (10), analysis of the association between various responses based on these data may therefore not be warranted.

An alternate explanation for the presence of HIV-1-specific immune responses in HEPS individuals is that these persons are infected with HIV-1, and that the infection is locally contained. This hypothesis could perhaps account for the persistence of both mucosal and systemic HIV-1-specific humoral and cellular immune responses. This possibility has recently been given credence by work from Corey and colleagues, who have amplified HIV-1 virus sequences from bulk CD4⁺ lymphocytes in a minority of HEPS subjects (35). While this hypothesis cannot be addressed by the current study, it should be noted that those HIV-1-resistant women enrolled in the current study have remained HIV-1 seronegative and PCR negative, in the face of normal CD4/CD8⁺ lymphocyte numbers, for many years. For instance, subject ML851 has been followed in the Pumwani clinic for 11 years, with CD4/CD8⁺ lymphocyte counts in 1998 of 880/mm³ and 320/mm³, respectively. Indeed, if these women have managed to contain HIV-1 infection...
for this considerable period of time, while the average time for progression to HIV-1 stage IVC disease in the Pumwani cohort is only 4.4 years (36), then further elucidation of immune responses in this group are still likely to be crucial to effective vaccine design.

The B57-restricted HIV-1 CTL epitope LSPRTLNAW, derived from the 24 region of A clade HIV-1, was recognized in several B8*76/B57*1 women from both HIV-1-infected and -resistant sex worker groups. This is not unexpected, given that cross-presentation of B57-restricted HIV-1 epitopes by the structurally related B*5801 molecule (which is more common in African populations) has been well described (37, 38). Similarly, the B7 restricted p24) were recognized in resistant sex worker ML851, who has B*8101 rather than B7; this is also likely to be due to cross-presentation by the closely related African B*8101 molecule (39, 40).

In summary, we have demonstrated CD8+ lymphocyte-mediated IFN-γ responses to HIV-1 CTL peptide epitopes in the cervix of highly exposed, uninfected Kenyan sex workers. The specificity of these responses was generally mirrored by systemic (PBMC) responses. These HIV-1-specific responses were enhanced in the genital tract at the likely site of repeated viral exposure and persisted in some subjects for up to 5 mo. These responses were shown to be mediated by CD8+ T cells using deletion experiments in both HIV-resistant and HIV-infected subjects and were not found in lower-risk control donors. These data suggest that HIV-1-specific CD8+ responses in the genital tract may play a role in protection against heterosexual HIV-1 infection in exposed, uninfected individuals.

Acknowledgments

We thank Erastus Irungu and Julius Oyugi for technical assistance; Dr. Joanne Embree, Dr. Lucy Matu, Dr. Craig Cohen, and Jane Kamene Musyoka for assistance in enrollment and follow-up of study subjects; and the women of the Pumwani clinic for their patience and cooperation throughout the study.

References


HIV-1-specific CD8+ responses in the cervix of highly exposed, uninfected Kenyan sex workers. The specificity of these responses was generally mirrored by systemic (PBMC) responses. These HIV-1-specific responses were enhanced in the genital tract at the likely site of repeated viral exposure and persisted in some subjects for up to 5 mo. These responses were shown to be mediated by CD8+ T cells using deletion experiments in both HIV-resistant and HIV-infected subjects and were not found in lower-risk control donors. These data suggest that HIV-1-specific CD8+ responses in the genital tract may play a role in protection against heterosexual HIV-1 infection in exposed, uninfected individuals.

Acknowledgments

We thank Erastus Irungu and Julius Oyugi for technical assistance; Dr. Joanne Embree, Dr. Lucy Matu, Dr. Craig Cohen, and Jane Kamene Musyoka for assistance in enrollment and follow-up of study subjects; and the women of the Pumwani clinic for their patience and cooperation throughout the study.

References


HIV-1-specific CD8+ responses in the cervix of highly exposed, uninfected Kenyan sex workers. The specificity of these responses was generally mirrored by systemic (PBMC) responses. These HIV-1-specific responses were enhanced in the genital tract at the likely site of repeated viral exposure and persisted in some subjects for up to 5 mo. These responses were shown to be mediated by CD8+ T cells using deletion experiments in both HIV-resistant and HIV-infected subjects and were not found in lower-risk control donors. These data suggest that HIV-1-specific CD8+ responses in the genital tract may play a role in protection against heterosexual HIV-1 infection in exposed, uninfected individuals.

Acknowledgments

We thank Erastus Irungu and Julius Oyugi for technical assistance; Dr. Joanne Embree, Dr. Lucy Matu, Dr. Craig Cohen, and Jane Kamene Musyoka for assistance in enrollment and follow-up of study subjects; and the women of the Pumwani clinic for their patience and cooperation throughout the study.

References


HIV-1-specific CD8+ responses in the cervix of highly exposed, uninfected Kenyan sex workers. The specificity of these responses was generally mirrored by systemic (PBMC) responses. These HIV-1-specific responses were enhanced in the genital tract at the likely site of repeated viral exposure and persisted in some subjects for up to 5 mo. These responses were shown to be mediated by CD8+ T cells using deletion experiments in both HIV-resistant and HIV-infected subjects and were not found in lower-risk control donors. These data suggest that HIV-1-specific CD8+ responses in the genital tract may play a role in protection against heterosexual HIV-1 infection in exposed, uninfected individuals.

Acknowledgments

We thank Erastus Irungu and Julius Oyugi for technical assistance; Dr. Joanne Embree, Dr. Lucy Matu, Dr. Craig Cohen, and Jane Kamene Musyoka for assistance in enrollment and follow-up of study subjects; and the women of the Pumwani clinic for their patience and cooperation throughout the study.

References


HIV-1-specific CD8+ responses in the cervix of highly exposed, uninfected Kenyan sex workers. The specificity of these responses was generally mirrored by systemic (PBMC) responses. These HIV-1-specific responses were enhanced in the genital tract at the likely site of repeated viral exposure and persisted in some subjects for up to 5 mo. These responses were shown to be mediated by CD8+ T cells using deletion experiments in both HIV-resistant and HIV-infected subjects and were not found in lower-risk control donors. These data suggest that HIV-1-specific CD8+ responses in the genital tract may play a role in protection against heterosexual HIV-1 infection in exposed, uninfected individuals.

Acknowledgments

We thank Erastus Irungu and Julius Oyugi for technical assistance; Dr. Joanne Embree, Dr. Lucy Matu, Dr. Craig Cohen, and Jane Kamene Musyoka for assistance in enrollment and follow-up of study subjects; and the women of the Pumwani clinic for their patience and cooperation throughout the study.

References


